The Manila Times

Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

Regulatory Milestone Adds to Fast-Track Designation Providing Further Potential Regulatory Advantages as Company Develops First-in-Class Mitochondrial Cell Therapy ...

D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering

NEW YORK CITY, NEW YORK / ACCESS Newswire / October 14, 2025 / On October 7, 2025, Humacyte, Inc. (Nasdaq:HUMA), a commercial-stage biotechnology platform company developing universally implantable, ...
The Manila Times

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combi ...
BioPharma Dive

FDA awards 9 companies a new ‘national priority’ voucher to speed drug reviews

A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...

Lords Mark Industries Ltd. secures US FDA Registration, Reinforces India’s Position in Global Healthcare Manufacturing

MUMBAI, India, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lords Mark Industries Ltd., has received US FDA registration for its range of surgical consumables, orthopedic supports, and hygiene products — a ...
Post Register

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever ...

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine ...

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...